TOP TEN perturbations for 1552863_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552863_a_at
Selected probe(set): 1552863_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552863_a_at (1552863_a_at) across 6540 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-3.8657856
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-3.7652192
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-3.6034465
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-3.5140529
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

adrenal gland cancer study 4 / normal adrenal cortex tissue

Relative Expression (log2-ratio):-1.9175825
Number of Samples:43 / 4
Experimental adrenal gland cancer study 4
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC).
Control normal adrenal cortex tissue
Histological normal adrenal gland cortical tissue samples derived after autopsy.

small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)

Relative Expression (log2-ratio):-1.8090572
Number of Samples:11 / 4
Experimental small cell lung cancer study 4 (XCL from CDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions.
Control small cell lung cancer study 4 (cell line)
Various small cell lung cancer (SCLC) publicly available cell lines samples.

chronic obstructive pulmonary disease study 30 / normal nasal epithelium tissue (never-smoker)

Relative Expression (log2-ratio):1.7978735
Number of Samples:50 / 54
Experimental chronic obstructive pulmonary disease study 30
Nasal epithelium obtained from patients who suffered from COPD GOLD I or II (mild-to-moderate COPD) and were current smokers. Subjects had early-stage COPD (FEV during the first second [FEV1]/ forced vital capacity [FVC] 70 %) and had a smoking history of at least 10 pack/years. Subjects in each of the groups were matched to subjects in the COPD group by age (±5 years), ethnicity, and sex using a match ID.
Control normal nasal epithelium tissue (never-smoker)
Nasal epithelium obtained from never smokers (NS). Subjects in each of the groups were matched to subjects in the COPD group by age (±5 years), ethnicity, and sex using a match ID.

HIF-2a depletion study 1 (normoxia; AB81) / HIF-1a depletion study 2 (normoxia; AB81)

Relative Expression (log2-ratio):-1.5577126
Number of Samples:3 / 3
Experimental HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-2a (Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.
Control HIF-1a depletion study 2 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):-1.4514523
Number of Samples:28 / 14
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they were alive.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they were alive.

BMP-9 study 1 / vehicle treated blood outgrowth endothelial cell sample

Relative Expression (log2-ratio):1.4452262
Number of Samples:3 / 4
Experimental BMP-9 study 1
Blood outgrowth endothelial cells (BOEC) treated for 4 hours with 1 ng/ml BMP9, bone morphogenetic protein 9 (in new media). Before treatment cells were kept for 12 hours in M199 media with 0.1% FBS. BOEC were generated from epithelial progenitor cells present in peripheral blood. Cells were cultured in EGM-2MV (10% FBS) and used for experiment between passages 4 and 8.
Control vehicle treated blood outgrowth endothelial cell sample
Blood outgrowth endothelial cells (BOEC) treated for 4 hours with vehicle (in new media). Before treatment cells were kept for 12 hours in M199 media with 0.1% FBS. BOEC were generated from epithelial progenitor cells present in peripheral blood. Cells were cultured in EGM-2MV (10% FBS) and used for experiment between passages 4 and 8.